Cardiac Amyloidosis Provider Education

TTRansforming Amyloidosis Care in Kentucky (Enduring)

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • Other: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Jun 6, 2023
  • Expires: Jun 5, 2026
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    (12 Ratings)


Gaurang Vaidya Gaurang Vaidya, MD
Assistant Professor of Medicine
Division of Cardiology
University of Kentucky
Lexington, Kentucky

Needs Statement

Often mistaken for more common heart failure, cardiac amyloidosis is a rare and serious disease that requires an accurate diagnosis and prompt treatment. Without treatment, the disease is fatal in a relatively rapid time frame. The treatment for cardiac amyloidosis is completely different than the other forms of heart failure. Early identification is now possible through non-invasive imaging techniques, and novel therapy is now available at the University of Kentucky, which can alter the outcome of the disease, thus transforming the care of the disease in the community.

Target Audience

The target audience for this course includes physicians, advanced practice providers, cardiac care associates, cardiovascular pharmacists, sonographers, nurses, and other practitioners who are involved in caring for cardiac amyloid patients or interested in the disease state.


Upon completion of this course, participants will be able to:

1. Recognize common manifestations of cardiac amyloidosis.

2. Develop appropriate clinical strategy for diagnosis of cardiac amyloidosis.

3. Restate new and upcoming medications

4. Identify and refer patients amenable to advanced heart failure therapies.


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

IPE Competencies

  • Roles/ Responsibilities

This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation. 


Supported by an unrestricted educational grant from Pfizer Inc.

In collaboration with UK Gill Heart & Vascular Institute.